Aktuellt
SENASTE
We think the fundamental reshaping of Bactiguard’s strategy in 2023, including lowering its cost base by finding partners for its BIP portfolio, laid the foundation for profitable growth ahead. The first step was taken in Q4, as the BD agreement was expanded with sales exclusivity for further markets; we expect news about the central venous catheter and endotracheal tube segments ahead. We also expect positive EBITDA towards the end of 2024.
LÄS MER
